Trial Profile
A Phase 2 clinical trial of Stemchymal for Spinocerebellar Ataxia (SCA)
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2018
Price :
$35
*
At a glance
- Drugs Adipose-derived stem cells-Steminent (Primary)
- Indications Spinocerebellar ataxias
- Focus Therapeutic Use
- 12 Sep 2018 New trial record
- 25 Aug 2018 According to a Steminent Biotherapeutics media release, the Company is currently working to initiate this trial in 2018.
- 18 Aug 2018 This is an orphan designated trial, according to a Steminent Biotherapeutics media release.